PURPOSE Nivolumab received US Food and Drug Administration approval as a single
agent or in combination with ipilimumab in patients with microsatellite instability …

Background Early detection and management of treatment‐related adverse events (TRAEs)
in patients receiving immune checkpoint inhibitors may improve outcomes. In CheckMate …

11 Background: In the phase 2 CheckMate 142 trial, nivolumab plus low-dose ipilimumab
provided robust and durable clinical benefit and was well tolerated as first-line therapy for …

Background In the phase II multicohort CheckMate 142 study, nivolumab plus low-dose (1
mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety …

Background: In previously chemotherapy-treated patients with MSI-H/dMMR mCRC from the
phase II CheckMate-142 trial, NIVO+ low-dose IPI (1 mg/kg) provided durable clinical benefit …

Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI,
20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously …

Background Immune checkpoint inhibitors (ICIs) are highly effective in patients with
microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer …

553 Background: Nivolumab (NIVO) provided durable responses (investigator-assessed
[INV] ORR, 31%) and disease control (DCR, 69%) in pretreated pts with dMMR/MSI-H …

519 Background: Approximately 4% of metastatic colorectal cancers (mCRCs) are
associated with high microsatellite instability (MSI-H), indicating a deficient DNA mismatch …

3501 Background: Evidence supports use of nivolumab (N) in MSI-H mCRC. N, a fully
human anti-PD-1 mAb and ipilimumab (I), a humanized anti-CTLA-4 mAb, have favorable …